JP5996553B2 - 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物 - Google Patents

果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物 Download PDF

Info

Publication number
JP5996553B2
JP5996553B2 JP2013547705A JP2013547705A JP5996553B2 JP 5996553 B2 JP5996553 B2 JP 5996553B2 JP 2013547705 A JP2013547705 A JP 2013547705A JP 2013547705 A JP2013547705 A JP 2013547705A JP 5996553 B2 JP5996553 B2 JP 5996553B2
Authority
JP
Japan
Prior art keywords
oral
item
mast cell
antihistamine
cromolyn sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013547705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014501287A5 (enExample
JP2014501287A (ja
Inventor
ジブ エム．ディー． ハリシュ，
ジブ エム．ディー． ハリシュ，
エフード アービット，
エフード アービット，
アイザック ルビンスタイン，
アイザック ルビンスタイン，
ラス ワインジマー，
ラス ワインジマー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2014501287A publication Critical patent/JP2014501287A/ja
Publication of JP2014501287A5 publication Critical patent/JP2014501287A5/ja
Application granted granted Critical
Publication of JP5996553B2 publication Critical patent/JP5996553B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013547705A 2010-12-30 2011-12-30 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物 Expired - Fee Related JP5996553B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98172610A 2010-12-30 2010-12-30
US12/981,726 2010-12-30
PCT/US2011/068185 WO2012092594A2 (en) 2010-12-30 2011-12-30 Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables

Publications (3)

Publication Number Publication Date
JP2014501287A JP2014501287A (ja) 2014-01-20
JP2014501287A5 JP2014501287A5 (enExample) 2015-02-26
JP5996553B2 true JP5996553B2 (ja) 2016-09-21

Family

ID=46383882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013547705A Expired - Fee Related JP5996553B2 (ja) 2010-12-30 2011-12-30 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物

Country Status (4)

Country Link
US (1) US20130017247A1 (enExample)
EP (1) EP2658538A2 (enExample)
JP (1) JP5996553B2 (enExample)
WO (1) WO2012092594A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX352824B (es) 2010-06-16 2017-12-11 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
US20140370086A1 (en) * 2010-12-30 2014-12-18 Ziv Harish Sublingual immunotherapy with reduced oral itchiness
EP3300734B1 (en) 2013-03-13 2019-08-14 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
JP2016512262A (ja) 2013-03-13 2016-04-25 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 血管炎の処置におけるレボセチリジン及びモンテルカストの使用
EP2969001B1 (en) * 2013-03-13 2018-12-19 IRR, Inc. Use of levocetirizine and montelukast in the treatment of anaphylaxis
CA2901410C (en) 2013-03-13 2023-09-12 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of traumatic injury
CN104546731A (zh) * 2013-10-09 2015-04-29 重庆安格龙翔医药科技有限公司 一种盐酸依匹斯汀颗粒剂及其制备方法
WO2015070116A2 (en) * 2013-11-11 2015-05-14 Harish Ziv M D Formulations and methods for prevention and treatment of oral allergy syndrome
CN105849958B (zh) * 2013-11-29 2019-10-29 旭化成株式会社 高分子电解质膜
US20160367520A1 (en) * 2014-02-10 2016-12-22 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
PT3104853T (pt) 2014-02-10 2020-01-14 Respivant Sciences Gmbh Tratamento com estabilizadores de mastócitos para distúrbios sistémicos
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
EP3740193A4 (en) * 2018-01-15 2022-03-02 Seattle Gummy Company SEMI-SOLID ANTHIHISTAMINE COMPOSITIONS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
CN110567949B (zh) * 2019-09-10 2021-12-14 广东天地和实业控股集团有限公司 细菌毒素检测方法及应用于该方法的处理仪

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064113A1 (en) * 2001-02-15 2002-08-22 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
WO2006045318A2 (en) * 2004-10-27 2006-05-04 Aarhus Universitet Diagnosis and treatment of immune-related diseases
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods

Also Published As

Publication number Publication date
WO2012092594A3 (en) 2012-10-26
WO2012092594A2 (en) 2012-07-05
US20130017247A1 (en) 2013-01-17
EP2658538A2 (en) 2013-11-06
JP2014501287A (ja) 2014-01-20

Similar Documents

Publication Publication Date Title
JP5996553B2 (ja) 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物
US12324838B2 (en) Intranasal epinephrine formulations and methods for the treatment of disease
EP1140093A2 (en) Compositions having improved delivery of actives
MXPA02003312A (es) Composiciones que tienen estabilidad mejorada.
KR102375232B1 (ko) 비강내 에피네프린 제제 및 질환의 치료 방법
US20130030009A1 (en) Method for the treatment and/or prevention of oral allergic symptions of the lips due to oral contact with a food allergen
HUP0105279A2 (hu) Javított stabilitású készítmények
US20250064897A1 (en) Topical administration of glp-1 receptor agonists
EP3068375B1 (en) Formulations and methods for prevention and treatment of oral allergy syndrome
HK40092206A (zh) 鼻内肾上腺素制剂及治疗疾病的方法
HK40121592A (en) Intranasal epinephrine formulations and methods for the treatment of disease
JP2023145488A (ja) ドライアイの処置のための組成物およびその使用の方法
HK40018410B (en) Intranasal epinephrine formulations and methods for the treatment of disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141229

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160824

R150 Certificate of patent or registration of utility model

Ref document number: 5996553

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees